Friday December 13, 2019 0 comments
DENVER -- United Cannabis Corporation (OTCBB: CNAB) announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for its application for a new patent that claims methods of using and preparing cannabinoid formulations.
The allowed application will mature into an issued patent once the issue fee is paid to the USPTO.
The allowed application is a divisional of the application that was previously allowed by the USPTO that matured into UCANN’s U.S. Patent No. 9,730,911 (the "'911 Patent").
The '911 Patent was issued Aug. 15, 2017.
"The new patent will compliment and will have the same priority date as our '911 Patent,” said Jesus Vazquez, UCANN VP and general counsel. It will be a valuable addition to the company's patent portfolio.
"The USPTO concluded that the claims in the new patent ‘are neither anticipated nor rendered obvious over the record.’ This is significant because the materials in the "record" that were reviewed by the USPTO include materials that our adversary in pending litigation has argued invalidate our '911 Patent.
“If those materials do not invalidate the claims in the new patent, they do not invalidate the claims in the '911 Patent."
"This development further confirms and protects our innovative approach to the advancement and use of cannabinoids for medical applications,” said Earnie Blackmon, UCANN CEO.
“As the broader medical and regulatory communities begin to recognize the opportunities within the sector it is increasingly important that we protect the innovations we have developed and the investment we have made along the way."